STOK Stock Forecast & Price Target

Stoke Therapeutics Inc has shown significant financial growth, with FY25 revenue reaching $184 million, largely attributed to a $165 million collaboration payment from Biogen, compared to $36.6 million in FY24. The advancements in the clinical development of zorevunersen, particularly the positive readouts from the ongoing phase I/II studies, indicate a strong potential for success in the upcoming registrational phase III EMPEROR study. Despite increased operating expenses of $205 million, which reflects a focus on research and development, the compelling efficacy and safety data associated with zorevunersen support a favorable outlook for the company's future performance in the biotechnology sector.

Stoke Therapeutics Inc. faces significant risks regarding its intellectual property, as the potential non-issuance or dispute of key patents could hinder market success, leading to revisions in its valuation. The company's financial position is also precarious, reporting a net loss of $6.9 million for the year 2025, with an expected lack of profitability for several years, necessitating additional capital raises that may dilute existing shareholder value. Furthermore, the inherent clinical and regulatory uncertainties associated with drug development add further financial risk, jeopardizing the successful commercialization of its product candidates.